The opposition between Polycomb repressive complexes (PRCs) and BAF (mSWI/SNF) complexes has a critical role in both development and disease. Mutations in the genes encoding BAF subunits contribute to more than 20% of human malignancies, yet the underlying mechanisms remain unclear, owing largely to a lack of assays to assess BAF function in living cells. To address this, we have developed a widely applicable recruitment assay system through which we find that BAF opposes PRC by rapid, ATP-dependent eviction, leading to the formation of accessible chromatin. The reversal of this process results in reassembly of facultative heterochromatin. Surprisingly,
The portion of the genome that may be subject to regulatory mechanisms appears to reflect a balance between chromatin processes that favor chromatin accessibility and those that oppose it. This balance was first recognized in Drosophila melanogaster, in which the Trithorax group of genes was shown to favor activation of developmental genes, while Polycomb genes were found to oppose this activation 1 . The Trithorax genes encode members of the BAP (Brahma-associated protein) ATP-dependent chromatin-remodeling complex and enzymes that produce the activating histone modification trimethylation of histone H3 at lysine 4 (H3K4me3) [2] [3] [4] . Genetically, Trithorax proteins act in opposition to Polycomb genes, which encode the subunits of the Polycomb repressive complex 1 (PRC1) and 2 (PRC2). PRC1 and PRC2 direct histone H2A ubiquitination (H2AK119ub1) and trimethylation of histone H3 at lysine 27 (H3K27me3), respectively, favoring inaccessible chromatin 5 . The presence of PRC1 and PRC2 is a mark of 'facultative heterochromatin' , which is distinguished from constitutive heterochromatin at centromeres and other regions of the genome.
Genomic studies have shown that the genes involved in creating the opposition between processes favoring and opposing chromatin accessibility are frequently mutated in human cancer. Subunits of the mammalian SWI/SNF or BAF (Brg/Brm-associated factor) complexes are mutated in more than 20% of all human cancers 6, 7 and a large number of human neurologic diseases [8] [9] [10] [11] . These complexes promote accessibility, at least in part, by opposing the actions of Polycomb complexes 12, 13 . The MLL genes encode catalytic subunits of the COMPASS complex that place the activation-associated H3K4me3 modification 14 . These genes are mutated in a large number of somatic cancers 4 . The catalytic PRC2 subunit EZH2 is mutated or silenced in a number of leukemias and lymphomas [15] [16] [17] .
In mammals, BAF complexes are 15-subunit assemblies that comprise different combinations of proteins, which are encoded by 29 genes. These highly polymorphic complexes can be exquisitely cell type specific, such as the nBAF complex found only in postmitotic neurons 18, 19 . The BAF subunit mutations found in human cancer have a striking pattern of tissue specificity. For example, nearly 100% of cases of human synovial sarcoma result from the SS18-SSX t(X;18) translocation (where SSX can be SSX1, SSX2, or SSX4); however, the SS18 BAF subunit is rarely mutated in other cancers. Malignant rhabdoid tumors (MRTs) uniformly result from deletions or loss-of-function mutations in SMARCB1 (also known as BAF47, INI1, or SNF5), but the SMARCB1 subunit is less frequently involved in other human cancers 20 . The present data indicate that the mechanisms of oncogenesis appear to relate to the ability of BAF complexes to oppose Polycomb-mediated repression. In human MRTs, loss of SMARCB1 leads to Polycomb-mediated repression of genes that suppress proliferation, such as CDKN2A 21 , while re-expression of SMARCB1 leads to removal of Polycomb from chromatin and loss of DNA methylation by unknown mechanism(s) 22 . Long time courses of re-expression in these earlier experiments were informative but did not allow for direct mechanistic analysis of the loss of Polycomb from chromatin, as loss could have been caused by differentiation, replication, or other cell biological actions. Nevertheless, the results of correlative studies suggest Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states 2 1 4 VOLUME 49 | NUMBER 2 | FEBRUARY 2017 Nature GeNetics A r t i c l e s that BAF might evict Polycomb at the CDKN2A locus. Conversely, in synovial sarcoma, the SS18-SSX oncogenic fusion protein, which is the product of the oncogenic allele, dominantly assembles into BAF complexes, targeting them to silenced Polycomb target genes where the altered BAF complex appears to remove Polycomb 23 . However, it is not known whether the BAF-Polycomb balance is achieved directly or indirectly, nor is there any knowledge of a causal sequence of biochemical events that provide this critical balance.
The mechanism underlying BAF-Polycomb opposition has been difficult to study. This is because present in vitro approaches using nucleosomal templates are unable to mimic the effects of tissuespecific histone modifications, long-range interactions, topological features, and post-translational modifications of the proteins involved. To elucidate the mechanism of BAF-Polycomb complex opposition, we developed a method to rapidly and reversibly recruit a chromatin regulator of interest to one allele of an endogenous gene and then measure and model the sequence of biochemical events that occur at this locus. We find that BAF complex recruitment evicts both PRC1 and PRC2 within 5 min and the development of chromatin accessibility follows. The order of deletion and reappearance predicts that PRC1 activity precedes PRC2 activity. This study shows that, in contrast to some expectations, BAF complexes oppose both PRC1 and PRC2 on a minute-by-minute basis without need for replication, Pol II occupancy, or transcription.
RESULTS

Development of an assay system to study the mechanism of BAF-Polycomb opposition
To study the opposition between BAF and Polycomb complexes at repressed facultative heterochromatin, we modified the endogenous Pou5f1 (also known as Oct4) locus, which in mouse embryonic fibroblasts (MEFs) is repressed by both Polycomb complexes 24, 25 and trimethylation of histone H3 at lysine 9 (H3K9me3) 26 is essential for Pou5f1 regulation 12, [27] [28] [29] (Supplementary Fig. 1a ).
To analyze the resolution of heterochromatin by BAF, we developed the CiAO (chromatin indicator and assay at Oct4) mouse by modifying one Pou5f1 allele to have two different arrays of transcription factor binding sites upstream of the transcription initiation site 30 ( Fig. 1a and Supplementary Fig. 1b ). In addition, the GFP coding sequence was inserted into the Pou5f1 allele, allowing the visualization of Pou5f1-expressing cells, but inactivating one allele. The allele containing the insertions is regulated similarly, both qualitatively and quantitatively, to the unmodified allele. In addition, the histone modification landscape of the modified allele is indistinguishable from that of the unmodified allele ( Fig. 1b and Supplementary Fig.  1c ). These observations indicate that both local and long-range topological features are not disturbed on the modified allele and that the insertions do not modify the pattern of histone modifications. The Pou5f1 allele containing the insertions is active in both pluripotent and germ cells derived from the CiAO mouse, but it is intensely repressed by Polycomb-group marks such as H3K27me3 and H3K9me3 in fibroblasts ( Fig. 1c) . The Pou5f1 locus undergoes repression upon embryonic stem cell (ESC) differentiation 30 , and in fibroblasts the gene can only be activated after prolonged exposure to the core pluripotency factors 31 . This system provides a broadly applicable model for developmental chromatin regulation, allowing the temporally precise addition of one or two specific factors within a context of normal chromatin. While signaling pathways such as the LIF-STAT3 cascade also induce chromatin changes, LIF responses are too diverse, involving many chromatin regulators, and too asynchronous to allow mechanistic interpretation 12, 32 . We used a chemical inducer of proximity (CIP), rapamycin, which induces proximity of proteins at the modified Pou5f1 allele by virtue of its ability to bind one protein tag (FRB) on one side and another tag (FKBP) on the other side of the rapamycin small molecule ( Fig. 1a) . Because rapamycin binding is limited by diffusion and the off-rate is on the order of seconds, this approach does not produce a rigid topology, but rather a cloud of complexes 33, 34 . This is in contrast to direct fusions, which produce rigid conformations that can sterically restrict the activity of the recruited proteins. Thus, the recruited BAF complex is free to assume its normal mode of binding to the Pou5f1 locus. To induce proximity of the BAF complex, we chose to fuse the SS18 subunit to FRB because SS18 A r t i c l e s remains stably associated with the BAF complex at concentrations of up to 5 M urea and is also a dedicated subunit 23, 35 (Fig. 1d ). We confirmed proper complex assembly of the FRB-V5-tagged SS18 subunit ( Supplementary Fig. 1d ), as well as FRB-V5-tagged SMARCB1 and SMARCE1 (also known as BAF57) subunits ( Supplementary Fig. 1e ).
We fused FKBP to the DNA-binding domain of the ZFHD1 zinc finger to facilitate binding at the ZFHD1 sites inserted ~250 bp upstream of the Pou5f1 promoter within a large repressed domain decorated with H2AK119ub1, H3K27me3, and H3K9me3 marks in fibroblasts ( Supplementary Fig. 1b) . We evaluated the feasibility and robustness of this system using three BAF complex subunit fusions and determined that, within 24 h, BAF complex recruitment was induced 40-to 60-fold over baseline levels and that the SS18-subunit-based recruitment was optimal ( Fig. 1e and Supplementary Fig. 1f ). This strategy is a chemical-genetic gain-of-function approach that only requires a few dozen binding events to induce recruitment to the single allele, thereby allowing the endogenous mTOR (FRB) and FKBP12 molecules to perform their normal functions 30, 33 .
Remarkably, addition of 3 nM rapamycin recruited the entire 2-MDa BAF complex to the Pou5f1 locus with a lag time of only 2 min (2.2 < t < 4.8 min, 95% confidence interval (CI)) at levels similar to BAF peaks over the genome of ESCs (Supplementary Fig. 1g ).
To be certain that the complexes were fully assembled, we performed ChIP experiments using antibodies to V5 (to capture the complexes bearing FRB-V5-SS18), as well as SMARCA4 and SMARCC1 (also known as BAF155). We found that each of these components was effectively recruited within 2-5 min of rapamycin addition ( Fig. 1f and Supplementary Fig. 1h) . Notably, the levels and extent of BAF binding when the rapamycin concentration was 3 nM were similar to those for BAF peaks over the genome 27 . BAF complexes occupied a region of approximately 1,200 bp, consistent with binding of a single 2-MDa complex 6 (Fig. 1g) . On the basis of published studies 36 , we calculated the fractional occupancy to be about 20% and the dwell time to be <83 s, indicating that the recruited complexes are maintained at this location in part by direct interactions with facultative heterochromatin. Thus, using this CIP system, BAF complexes can be recruited within minutes, at normal levels and with normal temporal dynamics.
Recruitment of BAF complexes results in rapid eviction of PRC complexes
Mutations of the Drosophila BAP (dSWI/SNF) ATPase brm entirely suppresses the effects of PRC1 mutations on body plan morphogenesis, attesting to the remarkable functional dedication of BAF and Polycomb 13, 37, 38 . Notably, disruption of the BAF-Polycomb opposition has become increasingly recognized as an oncogenic mechanism in several human cancers 21, 23, 39 . Therefore, we first measured the effect of BAF recruitment on PRC eviction ( Fig. 2a) . We found that recruitment of BAF led to the removal of both the PRC2 complex (EZH2) and the H3K27me3 mark within minutes ( Fig. 2b and  Supplementary Fig. 2a ). We also tested the alternative possibility that BAF recruitment removes PRC2 with subsequent loss of H3K27me3 by comparing the time courses of PRC2 and H3K27me3 removal after recruitment of the BAF complex. Unexpectedly, we found a full 10-min lag between the removal of PRC2 (EZH2) and the initial reduction of H3K27me3 levels (t(lag): 9.22 < t < 11.41 min) ( Fig. 2b) . This lag-time is unlikely to reflect differences in antibody detection, as the histone modification is more abundant than the enzyme. PRC2 works in synergy with PRC1 to repress genes 2 , and both Polycomb complexes and their associated histone marks are present at the repressed Pou5f1 locus in fibroblasts. In flies, mutations in PRC1 (pc1 or CBX6 subunit) are nearly completely repressed by mutations in the brm ATPase, demonstrating their opposition with one another 13 . Remarkably, PRC1 disappeared from the repressed Pou5f1 locus even more quickly than PRC2, as assayed by ChIP using an antibody that recognizes RING1B (Fig. 2c) . Eviction of PRC1 was paralleled by dissolution of the H2AK119ub1 (histone H2 ubiquitinated at lysine 119) repressive mark (Fig. 2c) . Decreased occupancy of the H2AK119ub mark preceded the decreased occupancy of the H3K27me3 mark (Fig. 2d) .
These observations raised the question of whether BAF-recruitment-mediated PRC displacement results from an increased rate of nucleosome or histone exchange. Previous studies have shown that BAF complexes can exchange nucleosomes in vitro, but this possibility has not been tested in vivo 40, 41 . We found that, within the first hour, there was no detectable change in the levels of H3K9me3 (the other prominent repressive mark at this locus), total histone H3 or histone H2A.Z, suggesting that the removal of H3K27me3 resulting from BAF complex recruitment does not reflect a non-specific enhancement of nucleosomal turnover ( Fig. 2d and Supplementary Fig. 2b) . This is consistent with our observation that deletion of BAF subunits, SMARCA4 and ACTL6A (also known as BAF53A) does not result in detectable genome-wide changes in nucleosome occupancy or placement as assayed by MNase-seq or ATAC-seq (E.L.M., D.C. Hargreaves, C.K., C. Chang, and J.P.C. et al., unpublished data).
Because we unexpectedly could not detect histone H3 depletion after BAF complex recruitment, we developed another mouse model system by double knock-in of the GAL4 and ZnDB DNA-binding sites and GFP reporter at the Ascl1 locus, which we call the CiAA (chromatin indicator and assay at Ascl1) mouse. Here we used the Ascl1 locus, which encodes the neuronal pioneer factor ASCL1. Ascl1 has both H3K27me3 and H3K4me3 marks over its regulatory regions and has a CpG island, which is often seen at PRC-marked sties 38, 42 . The Ascl1 promoter is occupied by RNA Pol II and is accessible (according to the Encyclopedia of DNA Elements (ENCODE) data). Hence, the histone marks of the Ascl1 locus in ESCs are quite different from those at Pou5f1 in fibroblasts. This difference allowed us to test the robustness of our findings to different loci over the genome. Addition of rapamycin resulted in robust recruitment of BAF to the Ascl1 locus (Supplementary Fig. 2c ). Similarly to Pou5f1 in MEFs, we found that BAF recruitment led to eviction of PRC1 and PRC2 within 2 min 43 . In contrast to the highly repressed Pou5f1 locus in MEFs, at the Ascl1 locus in ESCs, we were able to detect histone H3 turnover using CATCH-IT analysis 44 and also to observe depletion of histone H3 by ChIP analysis (Supplementary Fig. 2c) . Thus, it appears that Polycomb eviction occurs without detectable histone H3 or H3K9me3 depletion at the facultative heterochromatin of the Pou5f1 locus in MEFs, but histone H3 exchange is clearly detectable in ESCs at the accessible Ascl1 locus upon BAF recruitment. However, the time course of PRC1 eviction and the time course of histone H3 exchange at the Ascl1 locus were nearly identical, preventing us from assigning causality to either process at this locus.
We predicted that, if Polycomb contributed substantially to the repression of the Pou5f1 locus, we would find enhanced accessibility over the recruitment sites corresponding to either removal of the H3K27me3 mark or Polycomb complexes. We assayed chromatin accessibility using a modified ATAC-seq assay that measures the ability of the Tn5 transposase to invade open, but not closed, chromatin ( Supplementary   Fig. 2d,e) 45 . Remarkably, the development of accessibility, as reflected by lag-times, quickly followed the near-maximal removal of H3K27me3 and H2Aub1 (Fig. 2b,c,e ) Accessibility was restricted to the recruitment region of the locus and was not statistically significantly altered at more distant regions (Supplementary Fig. 2e) .
Our studies predict that BAF and PRC complexes should colocalize over the genome. Indeed, we found that 67% of BAF sites were co-occupied by PRC1 across the genome, suggesting that these two complexes may somehow interact (Supplementary Fig. 2f ). This level of co-occupancy is higher than that for PRC2 and PRC1, which are known to function synergistically 5, 38 . In other studies, we have found that BAF directly binds PRC1, but not PRC2, and releases it in an ATP-dependent mechanism 43 .
We were concerned that steric interference by recruitment of a large complex, several-fold larger than PRC1 and 12-fold larger than a nucleosome, could account for Polycomb eviction. Thus, we recruited the HELLS (also known as LSH) ATP-dependent chromatin remodeler. While addition of rapamycin effectively recruited these complexes to the Pou5f1 locus, we did not detect removal of PRC1 or the H2AK119ub1 repressive mark placed by the PRC1 complex ( Fig. 2f) , indicating that PRC eviction is a specific property of BAF complexes.
Finally, GFP expression from the altered Pou5f1 allele was not induced (Supplementary Fig. 2g) , likely owing to the substantial, unaltered repression by H3K9me3 (Fig. 2d) , DNA methylation, and the lack of recruitment of RNA Pol II (Supplementary Fig. 2h ).
Recent studies have suggested that loss of PRC2 repression only activates bivalent genes with the H3K4me3 mark 46 , which may perhaps explain the absence of gene activation upon Polycomb eviction. Thus, our system allows one to deconvolve the effects of these influences on accessibility in the absence of other variables. A r t i c l e s the underlying mechanisms, we studied the reassembly of Polycomb-repressed heterochromatin. This was achieved using FK1012 (ref. 34 ), a dimeric competitive inhibitor of rapamycin, which binds only to the FKBP side. FK1012 competed with rapamycin, rapidly removing it from the complex ( Fig. 3a and Supplementary  Fig. 3a) . In comparing the kinetics of rapamycin washout (via medium change) to the kinetics following addition of FK1012, we determined that addition of FK1012 resulted in more rapid, robust decreases in BAF complex tethering to the Pou5f1 locus (Fig. 3b) , enabling us to determine whether inaccessible heterochromatin could be reformed.
Repressed heterochromatin is re-established following BAF removal
We found that addition of FK1012 led to both the removal of BAF complexes within 15 < t < 30 min (Fig. 3b) , as assessed by anti-V5 ChIP, and the reappearance of PRC2 (EZH2) and H3K27me3 by 0.5 < t < 2.5 h (Fig. 3c) . We found that PRC2 (EZH2) and PRC1 (RING1B) complexes began to reappear within ~2 h of the addition of FK1012 and that this was paralleled by the reappearance of H3K27me3 and H2Aub1 (Fig. 3c,d) . The open, DNA-accessible state produced by BAF complex dissociation was not stable, as suggested by in vitro studies on nucleosomal templates 47 ; rather, inaccessible chromatin began to reform within 2.5-5 h of removal of the BAF complex ( Fig. 3e and Supplementary Fig. 3b-e ). These washout experiments mimic the developmental transition that occurs over many genes that are active in early development and later become repressed by Polycomb and facultative heterochromatin. Thus, our system allows one to make kinetic determinations in living cells of both dissolution and establishment of facultative heterochromatin.
Eviction of PRC and associated histone marks is dependent on the ATPase activity of SMARCA4
The ATPase activity of BAF complexes is provided by the SMARCA4 or SMARCA2 (also known as BRM) subunit, which is necessary for the function of BAF complexes in a variety of assays, and the ATPase domains are frequently mutated in cancer and neurologic diseases 39, 48 . Hence, we asked whether the ATPase activity of SMARCA4 was necessary for PRC1 and PRC2 eviction. To examine this, we directly recruited SMARCA4 by fusing the FRB tag to the C terminus of the protein. Recruitment of the BAF complex by this strategy was not as robust as it was with the fusion to SS18. However, we did find that the SMARCA4 fusion resulted in about a 4-to 8-fold increase in occupancy of SMARCC1 (BAF155) at the recruitment site as compared to the 40-to 60-fold increase seen with the SS18 fusion. To test the role of the ATPase activity of SMARCA4, we used a mutant (Lys785Arg) with reduced ATPase activity 49 that we originally reported by our group and is also found in a number of cancers and neurologic diseases 48 . Recruitment of this mutant SMARCA4 protein to the Pou5f1 locus in MEFs (Fig. 4a,b ) led to less PRC1 and PRC2 eviction than found with wild-type SMARCA4 (Fig. 4c,d) . Thus, the ATPase activity of SMARCA4 is required for PRC eviction. This result, along with the HELLS recruitment studies (Fig. 2f) , rules out the possibility that non-specific steric occlusion contributes to PRC eviction. The experiments above indicate that BAF complexes are capable of driving a transition from inaccessible higher-order chromatin structure toward accessibility, and that this transition is due to the direct eviction of both PRC1 and PRC2.
Recruitment of cancer-specific BAF complexes to repressed heterochromatin
BAF complexes can behave as either oncogenes or tumor suppressors. Unfortunately, it has not been possible to directly assay the effects of these tumor-suppressor or oncogenic mutations using in vitro assays. Hence, we asked whether we would be able to discern the mechanism of these oncogenic mutations using the CiAO assay. To this end, we recruited BAF complexes with highly specific driver mutations of complex subunits, which define specific cancer subtypes with Polycomb-repressed chromatin. To study the consequences of recruitment of BAF complexes lacking the SMARCB1 tumor-suppressor subunit, the hallmark feature of pediatric MRTs, we performed short hairpin RNA (shRNA)-mediated knockdown of Smarcb1 (knockdown efficiency >80%). We then recruited BAF complexes, using SMARCE1 as the FRB-V5-tagged subunit in this case because Smarcb1 knockdown results in slightly reduced SS18 binding to BAF complexes ( Figs. 1e and 5a, and Supplementary Fig. 1d ).
Complexes tagged with FRB-V5-SMARCE1, both wild type and depleted of SMARCB1, displayed comparable recruitment levels to the Pou5f1 locus (Fig. 5b,c) . Intriguingly, however, SMARCB1-depleted complexes exhibited significantly decreased ability to displace EZH2 (PRC2 complexes), RING1B (PRC1 complexes), and the H3K27me3 mark at the zinc-finger binding domain when compared to wild-type complexes (Fig. 5d-f ). This suggests that SMARCB1 loss in tumors leads to an inability to oppose Polycomb, mechanistically explaining the tumor-suppressive functions previously observed at CDKN2A and other loci 21 and supporting the therapeutic use of PRC inhibitors. BAF complexes can also be oncogenes that both initiate and drive cancer, as is the case with the SS18-SSX translocation that is found in nearly 100% of synovial sarcomas and in nearly 100% of the cells within the tumor. Hence, we sought to determine whether BAF complexes with the SS18-SSX fusion protein could oppose Polycomb. To perform these studies, we developed FRB-V5-SS18-SSX fusions for which we directly compared the results with our measurements using FRB-V5-SS18 (wild type) (Fig. 6a) . Using anti-SMARCA4 immunoprecipitation, we demonstrated that these complexes bear the expected features of BAF complexes containing the SS18-SSX fusion as demonstrated previously 23 , including reduced protein assembly of both SMARCB1 and wild-type SS18 (Fig. 6b) . Notably, SS18-SSX BAF complexes displayed a dramatically extended domain of BAF occupancy, spreading 2,620 ± 456 bp (95% CI) into the Pou5f1 gene body, as compared to complexes with wild-type SS18 (920 ± 305 bp (95% CI)), likely reflecting gained multimerization or processivity of the complexes (Fig. 6c) . While BAF complex recruitment at the zincfinger recruitment site (+0 bp) was comparable for wild-type SS18 and the SS18-SSX fusion over a 60-min time course ( Supplementary  Fig. 4a ), BAF complex occupancy at downstream sites >1,000 bp into the gene body was achieved only by SS18-SSX oncogenic BAF complexes ( Fig. 6c and Supplementary Fig. 4e) . Notably, SS18-SSX oncogenic BAF complexes robustly displaced both PRC2 and PRC1 complexes (Fig. 6d,e and Supplementary Fig. 4b,c,f,g) , as well as the H3K27me3 repressive mark ( Fig. 6f and Supplementary Fig. 4d,h) , at sites located at +1,034 bp and +2,287 bp with respect to the ZFHD1 recruitment site, while wild-type SS18 complexes were unable to achieve these effects outside of the 1,000-bp region flanking the ZFHD1 recruitment site. These results explain the robust removal of PRC2 and H3K27me3 over the entire SOX2 gene observed in synovial sarcoma.
DISCUSSION
Our studies indicate that the mechanism by which BAF complexes oppose Polycomb complexes is at least in part achieved through rapid eviction of PRC1 and PRC2 (Fig. 7) . The ATPase activity of SMARCA4 is required for eviction, suggesting that the process is specific and pointing toward possible mechanisms by which ATPasedead mutants act in human cancers. The fact that eviction occurs within 2-5 min of BAF recruitment indicates that neither cell replication nor transcription is necessary for Polycomb complex removal. These results illustrate the power of the CiAO system, which enables precise temporal control over the kinetics of BAF-Polycomb opposition. Because we could not detect the expected enhanced rates of nucleosome turnover for either histone H3 or H3K9me3, we speculate A r t i c l e s that loss of H3K27me3 reflects the natural rates of decay due to histone demethylases and basal rates of nucleosome removal 44 . Indeed, BAF has been reported to bind to H3K27 demethylases 50 , suggesting that it might recruit these enzymes to its sites of action. Chromatin accessibility rapidly follows the loss of H3K27me3 and H2Aub1, as expected from previous studies. In our CiAO system, we essentially modify the chromatin landscape of the Pou5f1 gene in MEFs to be more like that in ESCs, in which the gene is active and covered by a large domain of BAF. By removing the CIP through competition with FK1012, we revert the locus to one with inaccessible chromatin consistent with continuous opposition between BAF and Polycomb complexes, rather than a stable expression state based on nucleosome structure.
The mechanism of action that we describe in which BAF prepares a Polycomb-repressed locus for binding of transcription factors (Fig. 7) provides an explanation for the apparent instructive functions of specific BAF complexes. For example, switching the subunit composition to that of the neural-specific nBAF complex in human fibroblasts converts cells to a basal neuronal state that can be biased with specific transcription factors to produce types of neurons that have never been derived in culture from either ESCs or fibroblasts [51] [52] [53] . Instructive roles have also been reported in induced pluripotent stem cell (iPSC) conversion 54 , the heart field 55 , the wiring of the Drosophila olfactory system 56 , and induction of specific types of neurons in Caenorhabditis elegans 57 . Our model (Fig. 7) does not reduce the need for sequencespecific or linage-specific transcription factors in these biological processes, but rather suggests that BAF and its tissue-specific assem-blies act to open the range of possible binding sites for such factors and may possibly also aid in the positioning of nucleosomes to allow transcription factor binding.
Our studies indicate that loss of the SMARCB1 tumor-suppressor subunit, observed in MRTs, leads to substantially diminished eviction (Fig. 7f) . This mechanism predicts the observations in malignant cells suggesting that loci that repress proliferation, such as CDKN2A, become intensely repressed by a domain of H3K27me3 that builds over this gene, leading to a failure to halt cell division 21 .
The SS18-SSX fusion protein, which both initiates and drives synovial sarcoma, is an example of an instructive oncogenic function of an altered BAF complex 23 . Addition of only 78 amino acids of SSX onto the C terminus of the SS18 subunit leads to preferential assembly of the fusion protein into an oncogenic BAF complex that then targets the inactive SOX2 locus. The resulting complex removes Polycomb and activates expression of the SOX2 gene, thereby driving proliferation. This sequence of events largely precludes a mechanism in which a transcription factor recruits BAF because the SOX2 locus is inactive in the cell type that gives rise to the malignancy and the oncogenic BAF complex can activate the SOX2 gene in fibroblasts, in which the SOX2 locus is inactive and likely not occupied by transcription factors (Fig. 7g) . Our direct recruitment studies indicate that the role of the SS18-SSX fusion is to produce a complex that propagates along the chromosome to occupy a larger region than is normally occupied by BAF over the SOX2 gene in cells in which this gene is inactive. We find this larger region of occupancy in both BAF ChIP-seq studies in the malignant synovial sarcoma cells that bear the translocation 23 and also when we recruit the complex to the silent Pou5f1 locus in MEFs. Propagation of the complex leads to a larger domain of Polycomb removal and, hence, a greater chance that a transcription factor present in fibroblasts will bind to the now-accessible chromatin prepared by the oncogenic BAF complex. This scenario illustrates how these complexes can assume an instructive function (in this case, that function is uncontrolled proliferation) by allowing transcription factors present in fibroblasts to activate a gene normally only active in pluripotent cells and neural progenitors.
In the same way, the nBAF complex might prepare neural-specific genes for activation during reprogramming of fibroblasts to neurons 51, 52 . Thus, our studies provide an explanation for both the tumorsuppressor (SMARCB1 deletion in MRT) and oncogenic (SS18-SSX fusion in synovial sarcoma) functions of BAF complexes. Recent exome sequencing studies have highlighted striking frequencies of mutations in both BAF and Polycomb subunits in human cancers 39, 58 . Where studied, mutations in subunits of BAF complexes lead to altered Polycomb domains over the genome that have essential functions in either oncogenesis or pluripotency 12, 21, 23 . However, we and others were faced with an inability to discern whether Polycomb removal was direct or indirect, or whether replication or transcription was necessary for Polycomb removal. Our studies indicate that this widespread opposition is being constantly and directly waged and that its plasticity lends itself well to both developmental signaling and the balance between normal proliferation and tumor formation.
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